Company: NCEL
Filing Date: 2025-06-23
Form Type: F-4/A
Source: 0001213900-25-056787
Chunk: 127

Company: NewcelX Ltd.
Filing Date: 2025-06-23
Form: F-4/A
Chunk 127
---
 •identifying, assessing, acquiring and/or developing new product candidates; •accurately identifying demand for NLS’s product candidates; •continued consumer interest in treatments to the symptoms of narcolepsy, IH, ADHD and Long -COVID; •obtaining market acceptance of NLS’s product candidates, if approved for marketing, as viable treatment options; •negotiating favorable terms in any collaboration, licensing or other arrangements into which NLS may enter; •obtaining and maintaining CIV labeling (no FDA imposed boxed warning, commonly referred to as a “Black Box” warning) of NLS’s lead product candidate Quilience and follow -onproduct candidates, Nolazol and NLS -4; •establishing and nurturing relationships with the leading prescribers of narcolepsy, ADHD and Long -COVIDprescriptions in the United States; and •attracting, hiring, and retaining qualified personnel. Alexander Zwyer, its Chief Executive Officer, and Eric Konofal, its Chief Scientific Officer, have interests that may be different from, or in addition to, the interests of its shareholders and the Company and Aexon may not have sufficient funds to continue or grow operations. Alexander Zwyer owns 35% of Aexon, and Eric Konofal owns 59% of Aexon. Mr. Konofal is the founder of Aexon, with which NLS has a license agreement, and also serves as the President of Aexon. Mr. Zwyer holds no board or executive position at Aexon Labs, Inc., or Aexon. Mr. Zwyer and Mr. Konofal may have interests in the transactions with Aexon that may be different from, or in addition to, the interests of its shareholders and that may create potential conflicts of interest. Each of NLS and Aexon expect to be required to obtain additional liquidity in order to fund operations through the approval of certain of each of the company’s products. Until each company can generate significant revenues, if ever, each company expects to satisfy its future cash needs through debt or equity financings. Each company cannot be certain that funding will be available to it on acceptable terms, if at all. If funds are not available, each company may be required to delay, reduce the scope of, or eliminate research or development plans for, or commercialization efforts with respect to each company’s products. NLS expects that it will need to raise substantial additional funding before NLS can expect